Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptima Health Regulatory News (OPT)

Share Price Information for Optima Health (OPT)

Share Price is delayed by 15 minutes
Get Live Data
192.50    0.00 (0.00%)
Bid:
190.00
Ask:
195.00
Spread: 5.00 (2.632%)
Market Cap: £209.39m
OPT Live PriceLast checked at - London Stock Exchange

Intraday Optima Health Share Chart

Full Year Trading Update

16 Jun 2026 07:00

RNS Number : 3834I
Optima Health PLC
16 June 2026
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

 

Full Year Trading Update

 

LONDON, UK, 16 June 2026, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, today announces an unaudited trading update ahead of the publication of the Group's results for the year ended 31 March 2026.

Highlights

· Revenue for the year of approximately £121 million; 15% growth year-on-year (FY25: £105 million) in line with market expectations

· Other income of £4.7 million recognised relating to a previously disclosed procurement matter

· FY26 adjusted EBITDA expected to be c.10% ahead of previous market expectations as previously announced

· Completion of transformational £100 million acquisition of PAM Healthcare Limited ("PAM") on 26 March 2026, significantly enhancing scale and capability of the Group

· Integration activity is well underway with annualised synergies of £1.3 million already delivered as of 1 June 2026

· New business annualised wins of £10.8 million in FY26 [Optima only](FY25: £27.2 million) with a strong pipeline of new potential opportunities across the enlarged group including PAM

· Robust balance sheet with net debt (excluding leases) of £94.4 million as at 31 March 2026

 

Optima expects to report revenue for the full year of approximately £121 million, in line with market expectations, representing 15% growth versus FY25. As previously communicated, Optima expects FY26 adjusted EBITDA to be approximately 10% ahead of previous market expectations. Reflecting completion of the acquisition of PAM shortly prior to the year ended, the Group's net debt position (excluding leases) at 31 March 2026 was £94.4 million, comprising a cash balance of £21.6 million and £116 million of debt. Net debt at the end of May has reduced following repayment of the £30 million shareholder bridging loan associated with the acquisition of PAM, using net proceeds from the underwritten Open Offer equity raise which completed on 24 April 2026.

The Group has continued to make strong progress against its strategic objectives and mediumterm targets of achieving annual revenues of £200 million and £40 million of adjusted EBITDA. In line with the Group's strategy, Optima completed the transformational acquisition of PAM in March 2026 for total cash consideration of approximately £100 million. As one of the UK and Republic of Ireland's leading occupational health and wellness service providers, PAM is highly complementary and synergistic to Optima's existing operations. The integration of PAM is proceeding to plan and is expected to deliver significant revenue synergies, alongside operational and cost efficiencies. As of 1 June 2026 £1.3 million of annualised cost synergies have already been delivered.

The acquisition of PAM followed two strategic acquisitions by Optima during the first half of the year to further accelerate long-term growth and continue to increase the Group's market share, and broaden its capabilities, both in scope and geography.

Optima expects to report its Full Year Results for the year ended 31 March 2026 in August 2026.

 

Jonathan Thomas, Chief Executive Officer of Optima Health, said: "Optima's performance in FY26 demonstrates the momentum we are building as we deliver against our strategic objectives. Completing the acquisition of PAM during the year has expanded our capabilities and strengthened our ability to support customers across the UK and Ireland. As we look ahead, our priorities remain clear: maintaining high quality service delivery, progressing integration activities and our transformation programme, and advancing strategic initiatives to support the next phase of growth towards our stated ambition."

 

 

 

Enquiries

 

Optima Health

Jonathan Thomas, CEO

Heidi Giles, CFO

 

+44(0) 33 0008 5113

media@OptimaHealth.co.uk

Nominated Adviser and Joint Corporate Broker

Panmure Liberum Limited

Emma Earl / Will Goode/ Mark Rogers /

Rupert Dearden

Debt Advisory (sole debt adviser on the transaction):

Dan Howlett / Ben Handler

 

 

+44 (0)20 3100 2000

Joint Corporate Broker

Cavendish Capital Markets

Geoff Nash / Ben Jeynes / George Lawson /

Julian Morse / Michael Johnson/ Nigel Birks

 

+ 44 (0)20 7220 0500

 

UK Financial PR Adviser

ICR Healthcare

Mary-Jane Elliott / Angela Gray / Lindsey Neville

optimahealth@icrinc.com

 

 

 

About Optima Health

 

Optima Health is the UK's leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. With a team of more than 1,600 including 800 clinicians, Optima Health supports millions of employees and operates from a network of more than 50 clinics nationwide.

 

In addition to its core UK market, Optima Health also operates in Ireland under Optima Health Ireland, providing occupational health services to clients nationwide.

 

For more information visit www.optimahealth.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKPBBCBKDOAD
Date   Source Headline
16th Jun 20267:00 amRNSFull Year Trading Update
10th Jun 202611:46 amRNSHolding(s) in Company
9th Jun 20269:27 amRNSHolding(s) in Company
29th May 20268:34 amRNSHolding(s) in Company
27th May 202612:40 pmRNSHolding(s) in Company
18th May 202610:51 amRNSHolding(s) in Company
13th May 202612:12 pmRNSHolding(s) in Company
12th May 20265:32 pmRNSHolding(s) in Company
12th May 20261:00 pmRNSHolding(s) in Company
5th May 202610:22 amRNSHolding(s) in Company
5th May 20268:58 amRNSHolding(s) in Company
30th Apr 20263:36 pmRNSHolding(s) in Company
29th Apr 20266:02 pmRNSHolding(s) in Company
28th Apr 202610:39 amRNSHolding(s) in Company
28th Apr 20267:00 amRNSDirector/PDMR Shareholding
27th Apr 20264:27 pmRNSHolding(s) in Company
27th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 20263:57 pmRNSResult of GM and Underwritten Open Offer
17th Apr 20267:00 amRNSFull Year Trading Update
31st Mar 20267:00 amRNSLaunch of Underwritten Open Offer
30th Mar 20263:20 pmRNSHolding(s) in Company
24th Mar 20264:37 pmRNSIrish FDI Clearance & Expected Acquisition of PAM
23rd Mar 20267:00 amRNSDirectorate Change
12th Mar 20264:04 pmRNSHolding(s) in Company- Replacement
12th Mar 20267:00 amRNSContract Win
12th Mar 20267:00 amRNSContract Win
5th Mar 20263:50 pmRNSHolding(s) in Company
4th Mar 20263:33 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSDirector/PDMR Shareholding
16th Feb 20267:00 amRNSAppointment of Joint Broker
16th Feb 20267:00 amRNSAcquisition of PAM Healthcare Limited
9th Feb 20269:04 amRNSHolding(s) in Company
2nd Feb 20264:26 pmRNSHolding(s) in Company
10th Dec 20257:00 amRNSInterim Results
13th Nov 20257:00 amRNSNotice of Half Year Results
6th Nov 20252:17 pmRNSHolding(s) in Company
3rd Nov 20255:14 pmRNSHolding(s) in Company
3rd Nov 202511:15 amRNSHolding(s) in Company
3rd Nov 20257:00 amRNSHalf Year Trading Update
31st Oct 20252:00 pmRNSHolding(s) in Company
31st Oct 202511:06 amRNSHolding(s) in Company
20th Oct 20254:35 pmRNSHolding(s) in Company
29th Sep 20252:06 pmRNSHolding(s) in Company
23rd Sep 20257:00 amRNS-ROptima Health launches Optima Health Ireland
1st Sep 20254:06 pmRNSResult of AGM
4th Aug 202510:31 amRNSHolding(s) in Company
1st Aug 20252:55 pmRNSHolding(s) in Company
30th Jul 20257:00 amRNSNotice of AGM and posting of Annual Report
14th Jul 20253:21 pmRNSHolding(s) in Company
9th Jul 20256:02 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.